Patient characteristics
| Overall (n=45) | |
| Age (years) | |
| Median (minimum, maximum) | 67.6 (39.9, 84.6) |
| Gender | |
| female | 19 (42%) |
| male | 26 (58%) |
| Histology | |
| Adeno | 34 (76%) |
| Squamous | 10 (22%) |
| Sarcomatoid | 1 (2%) |
| PD-L1 expression | |
| 0 | 5 (11%) |
| >0–<10 | 0 (0%) |
| ≥10 | 28 (62%) |
| Not reported | 12 (27%) |
| T status | |
| 1 | 10 (22%) |
| 2 | 8 (18%) |
| 3 | 8 (18%) |
| 4 | 19 (42%) |
| N status | |
| 0 | 7 (16%) |
| 1 | 3 (7%) |
| 2 | 15 (33%) |
| 3 | 20 (44%) |
| M status | |
| 0 | 9 (20%) |
| 1 | 36 (80%) |
| UICC stage | |
| 3 | 9 (20%) |
| 4 | 36 (80%) |
| Immunotherapy regimen | |
| Atezolizumab | 3 (7%) |
| Nivolumab | 21 (47%) |
| Pembrolizumab | 20 (44%) |
| Ipilimumab/nivolumab | 1 (2%) |
| Treatment line | |
| First line | 25 (56%) |
| Non-first line | 20 (44%) |
| Prior surgery | 11 (24%) |
| Prior radiotherapy | 17 (38%) |
| Prior chemotherapy | 28 (62%) |
| Months immunotherapy until PET | |
| Median (minimum, maximum) | 30.7 (24.2, 53.0) |
| Months until best objective response | |
| Median (minimum, maximum) | 10.4 (1.1, 30.1) |
| Response according to RECIST | |
| PR | 36 (80%) |
| SD | 9 (20%) |
PET, positron emission tomography.